MedTrace Logo

Estrogen Replacement and Atherosclerosis (ERA) in Older Women

NCT00000549 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-03-16

No results posted yet for this study

Summary

To determine if estrogen replacement therapy, with or without low dose progesterone, slows progression or induces regression of coronary atherosclerosis in postmenopausal women.

Conditions

  • Cardiovascular Diseases
  • Coronary Arteriosclerosis
  • Coronary Disease
  • Heart Diseases
  • Myocardial Ischemia
  • Postmenopause

Interventions

DRUG

estrogen replacement therapy

DRUG

hormone replacement therapy

DRUG

estrogens

DRUG

progestins

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • David Herrington · Bowman Gray School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-08-31
Completion
2000-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000549 on ClinicalTrials.gov